SRAJ Stock Analysis 2026: Is PT Sejahteraraya Anugrahjaya Tbk Worth Buying?
 |
| PT Sejahteraraya Anugrahjaya Tbk |
Worldreview1989 - PT Sejahteraraya Anugrahjaya Tbk (IDX: SRAJ) is an Indonesian healthcare company best known for operating the Mayapada Hospital network. For investors accustomed to U.S. healthcare stocks such as HCA Healthcare, Tenet Healthcare, or Community Health Systems, SRAJ offers a familiar investment story: rising healthcare demand, hospital expansion, premium medical services, and long-term demographic growth.
However, SRAJ is not yet a straightforward growth-stock investment.
The company's revenue continues to grow, but profitability, leverage, interest expense, and valuation have become major concerns. In the first half of 2026, SRAJ generated approximately Rp1.30 trillion in revenue but recorded a Rp244.7 billion net loss.
That creates an important question for investors:
Can Mayapada Healthcare's long-term expansion justify the company's current financial risk and valuation?
For a U.S.-style investor, this is more important than simply asking whether Indonesia's healthcare market will grow.
SRAJ Stock: Quick Investment Overview
| Metric | SRAJ 6M 2026 |
|---|---|
| Company | PT Sejahteraraya Anugrahjaya Tbk |
| Stock ticker | SRAJ |
| Industry | Healthcare / Hospitals |
| Revenue | Rp1.302 trillion |
| Revenue growth | +9.5% YoY |
| Gross profit | Rp513.1 billion |
| Gross margin | 39.4% |
| EBITDA | Rp110.7 billion |
| EBITDA margin | 8.5% |
| Net income | -Rp244.7 billion |
| Net margin | -18.8% |
| Total assets | Rp7.62 trillion |
| Total equity | Rp1.09 trillion |
| Short-term debt | Rp158.0 billion |
| Long-term debt | Rp4.10 trillion |
| Cash | Rp1.53 trillion |
| Interest expense | Rp212.1 billion |
| EPS | -Rp19.99 |
The financial figures show a company with meaningful operating scale but weak bottom-line profitability.
The most important issue is therefore not revenue growth. It is whether SRAJ can convert revenue into sustainable free cash flow and net income.
What Does SRAJ Actually Do?
PT Sejahteraraya Anugrahjaya Tbk operates in Indonesia's private healthcare sector, with Mayapada Hospital as its most recognizable healthcare brand.
The company was established in 1991 and has been listed on the Indonesia Stock Exchange since 2011. Its business is primarily centered on private hospitals and healthcare services.
Mayapada Healthcare has expanded its hospital footprint over time.
According to the company's 2024 sustainability report, total bed capacity increased from 697 beds in 2022 to 861 beds in 2024, while the number of employees also increased substantially as the network expanded.
This matters because hospitals are fundamentally a capacity-utilization business.
Building hospitals requires significant upfront capital.
The investment thesis is that:
New hospital capacity → more beds → more patients → higher revenue → operating leverage → higher EBITDA → eventual improvement in free cash flow.
The problem is that this process can take several years.
Why American Investors May Find SRAJ Interesting
U.S. investors are familiar with hospital operators.
Companies such as HCA Healthcare have demonstrated how hospital networks can benefit from:
population growth,
higher healthcare utilization,
pricing power,
specialized medical services,
increased insurance coverage,
higher-acuity procedures, and
expansion into underserved markets.
SRAJ is attempting to develop a similar long-term healthcare infrastructure story in Indonesia.
The major difference is scale.
SRAJ is much smaller than the major U.S. hospital operators and therefore carries substantially greater execution and financing risk.
For an American investor, SRAJ should therefore be viewed more like a high-risk emerging-market healthcare growth company than a mature defensive healthcare stock.
SRAJ Revenue Is Growing — But Profitability Is the Problem
The company's 2025 results initially appeared encouraging from a revenue perspective.
SRAJ generated approximately Rp2.589 trillion of revenue in 2025, compared with Rp2.340 trillion in 2024, representing approximately 10.6% year-over-year growth.
Gross profit increased even faster, reaching approximately Rp1.059 trillion, up 15.5%.
That produced a gross margin of approximately:
Rp1.059 trillion ÷ Rp2.589 trillion = 40.9%
At first glance, this looks healthy.
But the company still reported a Rp199 billion net loss for 2025, compared with a Rp23.5 billion loss in 2024.
So investors need to distinguish between:
Revenue growth ≠ earnings growth.
That distinction becomes even more important in 2026.
SRAJ 6M 2026 Financial Analysis
The company's first-half 2026 results provide a much clearer picture.
According to the reported 2Q 2026 financial statements, SRAJ recorded:
Revenue: Rp1.302 trillion
Gross profit: Rp513.1 billion
EBITDA: Rp110.7 billion
Net loss: Rp244.7 billion
Revenue increased 9.5% YoY, but EBITDA fell approximately 50.4%, while the net loss expanded approximately 273% compared with 6M 2025.
This is a significant warning sign.
Simplified comparison
| Metric | 6M 2025 | 6M 2026 | Change |
|---|---|---|---|
| Revenue | Rp1.189T | Rp1.302T | +9.5% |
| Gross Profit | Rp462.5B | Rp513.1B | +10.9% |
| EBITDA | Rp223.2B | Rp110.7B | -50.4% |
| Net Loss | Rp65.6B | Rp244.7B | +273% loss |
This is arguably the most important data point in the SRAJ investment thesis.
The company is generating more revenue and gross profit, but EBITDA is deteriorating sharply.
For investors, that suggests the company's current problem is increasingly concentrated below the gross-profit line.
Why Is SRAJ Losing Money Despite Revenue Growth?
There are several factors investors should monitor.
1. Interest Expense
SRAJ's 6M 2026 interest expense was approximately Rp212.1 billion. EBITDA was only about Rp110.7 billion.
That means:
EBITDA / Interest Expense ≈ 0.52x
In simple terms, operating earnings before depreciation and amortization were insufficient to cover interest expense.
For a conservative investor, this is one of the biggest red flags in the company.
A mature healthcare company normally needs comfortable interest coverage because hospitals require substantial capital investment.
SRAJ currently does not have that cushion.
2. High Leverage
At the end of 6M 2026, SRAJ reported:
Cash: Rp1.53 trillion
Short-term debt: Rp158 billion
Long-term debt: Rp4.10 trillion
Equity: Rp1.09 trillion.
Using total debt of approximately Rp4.26 trillion:
Debt-to-Equity ≈ 3.9x
That is high.
A company with nearly four times as much debt as equity has limited room for operational mistakes.
The company therefore needs its new capacity and hospitals to eventually generate substantially higher earnings.
3. EBITDA Has Deteriorated
This is perhaps more concerning than the net loss itself.
SRAJ's EBITDA declined from approximately Rp223.2 billion in 6M 2025 to Rp110.7 billion in 6M 2026.
That represents a decline of more than 50%.
At the same time, revenue increased.
This creates a negative operating signal:
Revenue ↑
Gross profit ↑
EBITDA ↓↓↓
Net loss ↑↑↑
Investors should not ignore this pattern.
It suggests that simply growing the hospital network will not automatically create shareholder value.
The company needs to improve operating efficiency and utilization.
4. The Balance Sheet Is Under Pressure
SRAJ ended 2025 with approximately:
Rp7.62 trillion assets
Rp6.28 trillion liabilities
Rp1.34 trillion equity.
By 6M 2026, equity had declined further to approximately Rp1.09 trillion.
This is important because continued losses can gradually erode book value.
For investors who focus on balance-sheet strength, SRAJ currently does not look like a low-risk healthcare investment.
SRAJ Valuation: The Most Difficult Part of the Story
Valuation is where the SRAJ investment case becomes particularly controversial.
The reported 2Q 2026 figures showed a share price reference of approximately Rp12,500, market capitalization of roughly Rp153 trillion, and book value per share of approximately Rp89.15.
That implies a very high price-to-book ratio.
Using the reported numbers:
PBV ≈ Rp12,500 ÷ Rp89.15 ≈ 140x
This is an extremely high valuation relative to book value.
However, investors should be careful when interpreting this number.
A hospital company's economic value is not necessarily represented perfectly by its accounting book value because hospital assets, land, strategic locations, brands, and future capacity can have substantial economic value.
Nevertheless, a PBV above 100x requires very strong future earnings growth to justify the valuation.
Why P/E Is Not Useful for SRAJ Right Now
SRAJ is currently loss-making.
Therefore:
P/E = meaningless
when earnings are negative.
Instead, investors should focus on:
EV/EBITDA,
price-to-sales,
price-to-book,
normalized EBITDA,
interest coverage,
free cash flow,
debt maturity,
hospital utilization, and
future earnings power.
This is similar to how U.S. growth investors analyze companies that are still investing heavily before reaching normalized profitability.
SRAJ's Expansion Strategy
One of the biggest potential catalysts is additional hospital capacity.
Management has previously discussed the development of Mayapada Hospital Jakarta Timur (MHJT), with a planned capacity of more than 100 beds, while expansion of Mayapada Hospital Jakarta Selatan Tower 3 was also planned.
Expansion can create significant long-term revenue potential.
However, it also creates a classic healthcare infrastructure dilemma:
More hospitals require more capital before they generate mature cash flow.
The investment thesis therefore depends on whether new facilities can achieve sufficient patient volume and pricing relatively quickly.
The Bull Case for SRAJ
There is a credible long-term bullish argument.
1. Indonesia's Healthcare Market Has Long-Term Growth Potential
Indonesia has a large population and increasing demand for modern healthcare services.
As incomes rise and healthcare awareness improves, demand for:
specialist treatment,
cancer care,
cardiovascular services,
diagnostic services,
surgery,
premium private hospitals,
international-standard medical care
can increase.
This creates a structural opportunity for private hospital operators.
2. Mayapada Is Building a Premium Healthcare Brand
Mayapada Hospital has positioned itself toward higher-end medical services.
The company's annual report highlights international accreditation and healthcare standards, including Joint Commission International accreditation for Mayapada Hospital Jakarta Selatan.
That positioning may allow the company to target patients seeking premium medical services.
3. Hospital Expansion Could Create Operating Leverage
Hospitals have substantial fixed costs.
Once a new facility reaches a higher utilization rate, additional patients can potentially contribute disproportionately to operating earnings.
This creates the possibility of:
Revenue growth → utilization growth → EBITDA margin expansion → lower leverage → net profit recovery
If this happens, the current financial picture could look very different several years from now.
The Bear Case for SRAJ
The bear thesis is much simpler.
Revenue is growing, but earnings are not.
In 6M 2026:
Revenue +9.5%
but:
EBITDA -50.4%
and:
Net loss +273%.
This is not the financial profile investors normally want to see in an expensive growth stock.
Risk #1: Debt
High debt increases financial risk.
If hospital utilization takes longer than expected to improve, SRAJ could face:
higher interest costs,
refinancing risk,
weaker cash flow,
additional equity requirements,
slower expansion,
pressure on shareholder returns.
This is especially important because the company's interest burden is already significant.
Risk #2: Dilution
If the company needs additional capital, management could potentially raise funds through:
debt,
rights issues,
private placements,
strategic investors,
asset sales,
or other financing structures.
Additional equity issuance could dilute existing shareholders.
Therefore, investors should monitor changes in:
shares outstanding + debt + controlling shareholder ownership.
Risk #3: Valuation
A high valuation creates asymmetric downside.
When investors pay a very high multiple for a company that is currently losing money, future earnings must improve substantially.
If earnings disappoint, the stock can fall even if revenue continues growing.
This is a key lesson for U.S. investors:
A good company is not automatically a good stock at every price.
Risk #4: Execution
Opening a hospital does not automatically mean generating high returns.
Management must successfully execute:
doctor recruitment,
patient acquisition,
medical equipment investment,
hospital utilization,
insurance relationships,
BPJS relationships,
specialist services,
cost controls,
staffing,
and technology investment.
Execution risk is therefore substantial.
What U.S. Investors Should Watch
For an American investor researching SRAJ, I would monitor six metrics every quarter.
1. Revenue growth
Target:
>10% sustainable growth
Revenue growth alone is not enough, but it confirms demand.
2. EBITDA margin
This is critical.
The 6M 2026 EBITDA margin was approximately:
8.5%
versus roughly 18.8% in 6M 2025 based on the reported figures.
A recovery toward double-digit margins would be an important positive signal.
3. Interest coverage
The company needs EBITDA to comfortably exceed interest expense.
A major improvement from the current sub-1x level would strengthen the investment thesis.
4. Debt-to-equity
Investors should look for a sustained reduction from approximately 3.9x.
5. Free cash flow
This may ultimately matter more than accounting earnings.
A hospital company that consistently generates positive free cash flow has greater flexibility to:
repay debt,
fund expansion,
pay dividends,
or invest in new facilities.
6. Net income
Ultimately, SRAJ must return to sustainable profitability.
SRAJ Investment Scenario Analysis
Rather than making a simple "buy" or "sell" call, investors can think about three scenarios.
Bull Case
Assumptions:
Revenue continues growing >10% annually.
New hospitals ramp successfully.
EBITDA margin recovers.
Interest expense becomes manageable.
Net income turns positive.
Debt begins declining.
Under this scenario, SRAJ could potentially develop into a high-growth Indonesian healthcare company.
The stock could justify a premium valuation if earnings eventually catch up with expectations.
Base Case
Assumptions:
Revenue continues growing.
New facilities take several years to mature.
EBITDA gradually recovers.
Debt remains elevated.
Net income remains weak for several years.
Under this scenario, the company could continue expanding but shareholder returns may remain highly dependent on valuation.
Bear Case
Assumptions:
Revenue growth slows.
Hospital utilization disappoints.
EBITDA remains weak.
Interest costs remain high.
Losses continue.
Additional capital is required.
In this scenario, the high valuation could become a major problem.
The stock could experience significant downside even if the company's hospitals continue operating normally.
SRAJ vs. a Typical U.S. Healthcare Investor
A U.S. investor might compare SRAJ with mature healthcare companies.
| Factor | SRAJ | Mature U.S. Hospital Operator |
|---|---|---|
| Market | Indonesia | United States |
| Growth potential | High | Moderate |
| Current profitability | Weak | Generally stronger |
| Leverage risk | High | Varies |
| Scale | Small | Much larger |
| Healthcare demand | Strong structural trend | Strong |
| Expansion opportunity | Significant | More mature |
| Valuation risk | Very high | Generally easier to model |
| Currency risk for U.S. investor | High | Low |
| Political/regulatory risk | Emerging-market | Lower relative risk |
| Dividend thesis | Weak | Depends on company |
| Investment profile | High-risk growth | Mature growth/value |
This comparison illustrates the central SRAJ thesis:
SRAJ offers potentially greater growth, but investors are accepting considerably greater financial and valuation risk.
Is SRAJ a Good Stock to Buy in 2026?
For conservative investors, SRAJ currently does not look attractive based solely on its financial fundamentals.
The company has:
growing revenue,
an established healthcare brand,
expanding hospital capacity,
significant long-term healthcare-market exposure,
but also:
substantial losses,
high leverage,
weak interest coverage,
declining EBITDA,
declining equity,
and a very demanding valuation.
The 6M 2026 results are particularly concerning because revenue increased while EBITDA and net income deteriorated significantly.
Therefore, I would classify SRAJ as a:
High-Risk / High-Expectation Healthcare Growth Stock
rather than a conventional value investment.
My SRAJ Investment Scorecard
| Category | Score |
|---|---|
| Healthcare industry outlook | 8/10 |
| Revenue growth | 7/10 |
| Brand / hospital network | 7/10 |
| Expansion opportunity | 8/10 |
| Current profitability | 3/10 |
| EBITDA trend | 3/10 |
| Balance sheet | 3/10 |
| Interest coverage | 2/10 |
| Valuation | 2/10 |
| Dividend appeal | 1/10 |
| Long-term potential | 7/10 |
| Overall risk | High |
Overall SRAJ investment rating: 5/10 — Speculative / Watchlist
This does not mean the company cannot become successful.
It means the current financial numbers require a significant improvement before the stock can be considered a conventional fundamentally attractive healthcare investment.
What Could Change My View?
There are several developments that could materially improve the investment thesis.
I would become more constructive if SRAJ demonstrates:
1. EBITDA margin recovery
A move back toward 15%+ would be encouraging.
2. Positive free cash flow
This would demonstrate that the business can finance itself.
3. Debt reduction
Lower leverage would reduce financial risk.
4. Positive net income
A return to sustainable profitability would make valuation analysis significantly easier.
5. Strong utilization of new hospitals
New facilities must transition from capital-consuming assets into cash-generating assets.
6. Lower interest burden
This could have a major impact on net earnings.
Final Verdict
PT Sejahteraraya Anugrahjaya Tbk represents an interesting but highly speculative way to gain exposure to Indonesia's growing private healthcare market.
The company's Mayapada Hospital platform, expanding bed capacity, premium healthcare positioning, and Indonesia's long-term healthcare demand create a legitimate growth story.
But the financial results tell investors to remain cautious.
In 6M 2026, SRAJ generated Rp1.30 trillion of revenue, yet suffered a Rp244.7 billion net loss, while EBITDA declined more than 50% year over year. Interest expense was approximately Rp212.1 billion.
That combination makes the current investment case highly dependent on future operational improvement.
The investment thesis in one sentence:
SRAJ could become a valuable Indonesian healthcare growth story if its new hospital capacity produces strong utilization, higher EBITDA margins, positive free cash flow, and lower leverage—but the 2026 financial results show that this turnaround has not yet been proven.
For investors following SRAJ, the most important question is therefore not:
"Will Indonesia's healthcare market grow?"
It probably will.
The more important question is:
"Can SRAJ convert that healthcare growth into enough cash flow and earnings to justify its financial leverage and valuation?"
That is the question investors should watch in every upcoming quarterly report.
Primary and Credible References
Mayapada Healthcare / PT Sejahteraraya Anugrahjaya Tbk — 2024 Annual Report, including company profile, hospital network, accreditation and operational information.
Mayapada Healthcare — 2024 Sustainability Report, including bed capacity, patients served and employee data.
Mayapada Healthcare — Annual Public Expose, providing corporate and strategic information regarding SRAJ.
SRAJ Consolidated Interim Financial Statements, including financial information and healthcare-related agreements.
SRAJ 1Q 2026 Financial Statements, reporting first-quarter 2026 revenue, EBITDA, net loss, debt and equity.
SRAJ 2Q 2026 Financial Statements, reporting the latest available 6M 2026 financial performance.
Otoritas Jasa Keuangan (OJK) — Indonesia's financial-services regulator and capital-market supervisory authority.
Disclaimer
This article is for educational and informational purposes only. It is not personalized investment advice or a recommendation to buy or sell SRAJ shares.
Investors should review SRAJ's latest financial statements, corporate disclosures, material transactions, debt obligations, and risk factors before making an investment decision.
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group